Kenvue product management interviews test whether candidates understand how to develop and manage consumer health products across a portfolio of iconic brands – Tylenol, Neutrogena, Listerine, Band-Aid, Aveeno, Zyrtec, Benadryl, Johnson's Baby, and others – where the intersection of FDA regulatory compliance for OTC drug products, consumer preference research, retail shelf economics, and the innovation pipeline decisions that sustain category leadership all require product management judgment that goes beyond general consumer goods product development. Product management at Kenvue is the world's largest pure-play consumer health company – spun off from Johnson & Johnson in 2023 with approximately $15 billion in revenue across more than 165 countries – and must balance the innovation investment required to keep heritage brands relevant against the regulatory complexity of modifying OTC drug products (which require FDA review), the retail channel requirements that determine which innovations actually reach consumers, and the competitive pressure from private label products and newer direct-to-consumer brands that challenge Kenvue's premium brand positioning. The product management challenge is distinctive because Kenvue's portfolio spans both FDA-regulated OTC drug products (where product changes require regulatory submissions and approval timelines measured in years rather than months) and cosmetic and personal care products (where faster innovation cycles are possible but consumer trust and efficacy communication standards are high). Interviewers evaluate whether candidates understand consumer health product development, OTC drug regulatory strategy, and how to sustain category leadership across iconic brands that consumers have trusted for decades while innovating to meet evolving consumer preferences.
Start your free Kenvue Product Management practice session.
What interviewers actually evaluate
Consumer health OTC product management versus general consumer goods or pharmaceutical product management
Kenvue product management interviews probe whether candidates understand how managing FDA-regulated OTC drug products differs from general consumer goods product management in the regulatory approval requirements, label claim constraints, and the evidence-based innovation standards that govern what can be changed and how quickly. A general consumer goods product manager can reformulate a shampoo or change a food product's flavor profile with relatively limited regulatory review; a Kenvue product manager who wants to add a new active ingredient to a Tylenol formulation, modify the dosing instructions for a Zyrtec product, or introduce a new drug delivery system for Benadryl must navigate FDA's OTC drug monograph system (which governs which active ingredients, concentrations, and uses are generally recognized as safe and effective) or pursue a new drug application (NDA) for innovations outside existing monograph coverage. This regulatory framework creates product development timelines and constraints that require product managers to plan innovation investments years in advance and to prioritize which innovations are worth the regulatory investment.
Consumer brand renovation versus innovation is evaluated as a core Kenvue product management competency. Renovation – updating existing products (improved formulations, new formats, packaging redesigns, line extensions within existing categories) – is the engine of consistent volume growth for established brands like Tylenol, Neutrogena, and Listerine. Innovation – developing genuinely new product concepts that open new need states or create new category segments – requires larger investments and longer development timelines but creates the platform expansions that sustain brand growth over decades. Product management must allocate development resources between renovation (which generates more predictable, near-term returns) and innovation (which carries higher uncertainty but creates longer-term competitive advantage), while ensuring that the regulatory complexity of OTC drug products doesn't consume so much capacity that innovation pipeline investment is crowded out by ongoing compliance work.
What gets scored in every session
Specific, sentence-level feedback.
| Dimension | What it measures | How to answer |
|---|---|---|
| OTC drug product development and regulatory strategy | FDA OTC monograph navigation, drug product label claims, regulatory submission strategy for consumer health products | Demonstrate OTC drug product management with specific regulatory strategy and label claim development process for FDA-regulated consumer health products |
| Brand renovation and innovation portfolio management | Renovation pipeline prioritization, innovation investment against brand growth needs, new format and line extension strategy | Show consumer health brand product portfolio management with specific renovation and innovation balance methodology and pipeline contribution metrics |
| Consumer insight-driven product development | Claim substantiation research, consumer preference testing, unmet need identification for health and wellness products | Give examples of consumer insight methodology with specific research approach and insight-to-product-development translation for consumer health categories |
| Retail channel product strategy and shelf performance | SKU rationalization, retail-specific product formats, promotion-led and everyday product line architecture | Articulate consumer health retail product strategy with specific channel product line management and shelf performance optimization approach |
How a session works
Step 1: Choose a Kenvue product management scenario – OTC drug product development and FDA regulatory strategy, brand renovation and innovation portfolio planning, consumer insight and unmet need identification for health products, or retail channel product line architecture and shelf optimization.
Step 2: The AI interviewer asks realistic Kenvue-style questions: how you would develop the innovation strategy for the Tylenol brand that identifies the next product platform expansion beyond the existing pain relief line while navigating FDA's OTC drug monograph requirements that constrain which active ingredient changes require formal review, how you would manage the Neutrogena facial skincare line renovation program that updates formulations to meet consumer demand for cleaner ingredient profiles without compromising the dermatological efficacy that is the Neutrogena brand's core equity, or how you would design the consumer research program that identifies unmet needs in the children's cough and cold category where Kenvue's existing products compete in a challenging regulatory environment post-FDA's 2008 guidance restricting cold and cough products for children under 12.
Step 3: You respond as you would in the actual interview. The system scores your answer on OTC regulatory strategy, brand portfolio management, consumer insight methodology, and retail product strategy.
Step 4: You get sentence-level feedback on what demonstrated genuine consumer health product management expertise and what needs stronger OTC regulatory or brand innovation framing.
Frequently Asked Questions
How does FDA's OTC drug monograph system affect Kenvue's product development?
The FDA OTC drug monograph system establishes the conditions under which OTC drug products are generally recognized as safe and effective (GRASE) without requiring individual product approval. Active ingredients, permitted concentrations, approved uses, and required labeling language are specified in the monograph for each drug category (pain relief, antihistamines, antacids, oral antiseptics, and others). Kenvue product development must work within monograph conditions – Tylenol must contain acetaminophen at approved concentrations with approved dosing instructions; Zyrtec must contain cetirizine at the approved OTC dose. Product innovations that work within existing monograph conditions (new dosage forms like gel caps or dissolving strips, new product formats that use the same approved active ingredient) can typically be commercialized with 510(k) or OTC monograph compliance review rather than full NDA submissions. Innovations outside existing monograph conditions – new active ingredients, new combinations, new uses – require FDA approval through the NDA process, which adds years to the development timeline.
How does Kenvue manage brand renovation for iconic brands like Tylenol and Listerine?
Renovation for established OTC brands involves updating products within the constraints of FDA label requirements while responding to consumer preference trends. Tylenol renovation has included format innovation (Tylenol Rapid Release Gels for faster absorption perception, Tylenol Dissolve Packs for consumers who have difficulty swallowing tablets), packaging innovation (child-resistant packaging improvements, dose indicator packaging), and line extension into condition-specific products (Tylenol Arthritis Pain, Tylenol PM with sleep aid). Listerine renovation has followed oral health research (Listerine Total Care, Listerine Healthy White, Listerine Gum Therapy) that extends the brand beyond its core mouthwash positioning into specific oral health conditions. Product management must evaluate each renovation's incremental volume potential (does it genuinely address a consumer need or is it SKU proliferation?) and retail shelf economics (does the retailer benefit from carrying the new SKU, or does it cannibalize an existing item without expanding the category?).
How does the J&J spinoff affect Kenvue's product development capabilities?
Kenvue's separation from Johnson & Johnson in 2023 created both opportunities and challenges for product development. As part of J&J's large healthcare R&D ecosystem, Kenvue's product development had access to J&J's pharmaceutical research infrastructure, clinical trial capabilities, and regulatory expertise that supported the development of consumer health products with strong clinical evidence bases. As an independent company, Kenvue must maintain these capabilities through its own R&D investment and through external partnerships (with universities, contract research organizations, and ingredient suppliers) that provide research capabilities beyond Kenvue's internal capacity. The benefit of independence is focus – Kenvue's R&D investment is entirely directed toward consumer health rather than competing with J&J's pharmaceutical and medical device priorities for research resources.
How does Kenvue approach product development for international markets?
Kenvue operates in more than 165 countries with different regulatory frameworks, consumer preferences, and competitive dynamics for its brands. International product development involves: regulatory assessment for each target market (each country's regulatory agency has its own OTC drug approval requirements that may differ from FDA – Neutrogena sunscreen formulations approved in the US may require reformulation for EU markets where certain UV filters are not approved), consumer adaptation (flavor profiles for Listerine, scent preferences for Aveeno, and skin type diversity for Neutrogena may require product modifications for different cultural preferences), and market-specific innovation (some Kenvue products are developed for specific international markets based on local health needs or competitive conditions). Brand consistency across markets is important for Kenvue's global brands, but local adaptation is often necessary for regulatory compliance and consumer relevance.
How does Kenvue compete with private label in product development?
Retailer private label OTC products are manufactured to equivalent active ingredient specifications as Kenvue's branded products – a Walmart Equate acetaminophen tablet is chemically equivalent to a Tylenol tablet. Kenvue's product development response to private label competition focuses on dimensions that private label cannot replicate: format differentiation (Tylenol's line of specialty formats – Rapid Release Gels, Dissolve Packs, Sinus Congestion & Pain – provide consumer-preferred delivery formats that private label typically doesn't replicate), brand-specific innovations in personal care (Neutrogena's Retinol formulations and Aveeno's Oat Science ingredient technology represent proprietary innovation that creates genuine efficacy differentiation from generic alternatives), and consumer trust built through clinical evidence and healthcare professional endorsement (Tylenol's relationships with physicians and pharmacists who recommend it for specific populations – acetaminophen is recommended for patients who cannot take NSAIDs – provides recommendation-driven purchase that private label cannot displace).
Also practice
One full session free. No account required. Real, specific feedback.
